Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide

Haematologica

Volumn 93, Issue 2, 2008, Pages 315-316

  Eclache, Virginie ^a   Da Rocha, Anna ^a   Le Roux, Génevieve ^a   Fenaux, Pierre ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

Case study; Del(5q) MDS; Lenalidomide; Myelodysplastic syndromes; Transfusion dependent

Indexed keywords

IMATINIB; LENALIDOMIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLONE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG WITHDRAWAL; DYSERYTHROPOIESIS; FEMALE; GENE DELETION; HUMAN; LYMPHOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 5; DRUG RESISTANCE; FEMALE; HUMANS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; SEQUENCE DELETION; THALIDOMIDE;

EID: 40849131212     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11917     Document Type: Article

References (10)

1. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 1974;251:437-8 .
2. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 2004; 18:113-9.
3. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-65.
4. Bernard M, Lemee F, Picard F, Ghandour C, Drenou B, Le Prise PY, Lamy T. Jumping translocation in acute leukemia of myelomonocytic lineage: a case report and review of the literature. Leukemia 2000;14:119-22.
5. Najfeld V, Hauschildt B, Scalise A, Gattani A, Patel R, Ambinder EP, et al. Jumping translocation in leukemia. Leukemia 1995;9:634-9.
6. Busson le Coniat M, Brizard F, Smadja NV, Maarek O, Der Sarkissian H, Berger R. Intertitial telomere repeats in translocation of hematopoietic disorders. Leukemia 2000;14:1630-3.
7. Wan TS, Ma SK, Chow EY, Li YH, Lin SY, Chan LC. Pathogenesis of jumping translocations: a molecular cytogenetic study. Leuk Res 2004;28:1075-9.
8. Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005;69:56-63.
9. Pellagatti A, Jädersten M, Forblom AM, Cattan H, Christenson B, Emanuelsson E, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA 2007;104:11406-11.
10. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16: 2190-6.